<DOC>
	<DOCNO>NCT00331071</DOCNO>
	<brief_summary>The purpose study assess occurrence venous thromboembolism ( blood clot ) , stroke , heart attack current user ORTHO EVRA compare current user norgestimate-containing oral contraceptive 35 mcg ethinyl estradiol special attention duration use . The study use data PharMetrics Patient-Centric Database MarketScan database , US medical claim database .</brief_summary>
	<brief_title>Postmarketing Study ORTHO EVRA ( Norelgestromin Ethinyl Estradiol Contraceptive Patch ) Relation Venous Thromboembolism ( Blood Clots ) , Stroke Heart Attacks</brief_title>
	<detailed_description>ORTHO EVRA newly develop transdermal ( absorbed skin ) contraceptive ( birth control ) system ( `` patch '' ) available U.S. since April 2002 . The study use data PHARMetrics MarketScan database assess occurrence venous thromboembolism ( blood clot ) , ischemic stroke ( blockage artery supply blood brain ) , acute myocardial infarction ( heart attack ) current first time user ORTHO EVRA compare current first time user norgestimate-containing oral ( mouth ) contraceptives 35 mcg ethinyl estradiol . The PHARMetrics database ongoing longitudinal database information 17 million people . It make data contribute manage care plan United States contain information pay claim pharmaceutical , medical diagnosis procedure , demographic ( age , race , etc ) information . There 3 set case reflect woman first-time record claim ICD-9 ( International Classification Diseases , ninth revision ) diagnosis study period ( ) venous thrombosis pulmonary embolism ( blood clot lung ) hospitalization study period subsequent claim anticoagulant treatment , ( b ) ischemic stroke hospitalize , ( c ) acute myocardial infarction acute coronary revascularization ( restoration blood supply heart ) hospitalize . Three separate set control ( patient ) identify outcome . One analysis estimate relative risk idiopathic ( unknown cause ) ischemic stroke myocardial infarction , another analysis estimate relative risk idiopathic venous thromboembolism ( deep vein thrombosis pulmonary embolism ) . A specific analysis call `` Conditional logistic regression '' ( conditional matching factor ) use study . Analyses stratify calendar year . The analysis repeat include non-idiopathic ( ie , know cause ) case venous thromboembolism , stroke , heart attack . The original study run March 2005 , update August 2006 , October 2007 . A transdermal patch contain 6 mg norelgestromin ( NGM ) 0.75 mg ethinyl estradiol ( EE ) wear 1 week replace weekly 3 consecutive week ; fourth week patch-free . Monophasic ( pill hormones concentration ) triphasic ( 3 different pill take cycle ) oral contraceptive pill take 21 consecutive day follow pill drug-free pill 7 day .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Ortho Evra</mesh_term>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Users Ortho Evra first time user norgestimatecontaining oral contraceptive 35 mcg ethinyl estradiol April 1 , 2002 December 31 , 2004 , identify PHARMetrics database use National Drug Code ( NDC ) assign FDA modify Pharmetrics 6 month enrollment health plan prior event date match case Start study contraceptive use January 1 , 2002 Updates original study include user Ortho Evra first time user norgestimatecontaining oral contraceptive identify PHARMetrics database US healthcare claim database August 2006 October 2007 Patients ICD9 code cancer ( except nonmelanoma skin cancer ) , renal failure , chronic inflammatory disease</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Hormonal contraception</keyword>
	<keyword>Oral contraception</keyword>
	<keyword>Ethinyl estradiol , Progestin , Contraception</keyword>
	<keyword>Transdermal</keyword>
</DOC>